Loading...
History 2021-02-02T17:17:08+00:00

History

2021
JANSubcutaneous injection (SC) Hybrozyme Technology Signed a two-digit loyalty base technology transfer contract with Intas
JANAltos Biologics, a subsidiary of Alteogen, completed an investment of 60.5 billion won
JAN Maintaining and expanding exclusive rights with the PCT application for additional human hyaluronidase
JANClinical entry for global product release of sustainable human growth hormone
2020
DECRecombinant human hyaluronidase finished product Tergase application for clinical IND application
DECReceived the 10 Million Dollar Export Tower
DECIlia biosimilar domestic clinical patient administration completed
NOVRecruiting overseas research experts to expand R&D
NOV Established Altos Biologics, a subsidiary of Alteogen, enters Phase 3 clinical trials for Ilia Biosimilar
OCTADC breast cancer ADC gastric cancer treatment-combination development promotion
OCTSecuring global competitiveness in the production method patent for Ilia biosimilar fusion protein
SEPCompleted the first phase 1 clinical trial in Korea for ADC breast cancer treatment
AUGRecombinant human hyaluronidase manufacturing method patent application
JULFiled process patent for manufacturing of blood coagulation factor VII/VIIa fusion proteins
JULSelected as ‘2020 KOSDAQ Rising Star’ by Korea Exchange
JUNEntered Non-exclusive License Agreement with top 10 global pharmaceutical company for ALT-B4 technology
JUNRegistered patent for modified antibody conjugated with a motif containing a cysteine residue (Europe)
MAYPresented phase 1 summary of ADC breast cancer treatment at Abstract Notification_2020 ASCO annual meeting ADC
APRRegistered formulation patent for Eylea biosimilar (Canada, Australia)
MARFiled International PCT for an antibody treatment for subcutaneous injection such as Herceptin SC, Rituxan SC, and Keytruda SC
MARCompleted phase 1 clinical trial in Korea for ADC breast cancer treatment
FEBSelected as an excellent corporation for public announcement by Korea Exchange in 2019
FEBFirst patient in for Eylea biosimilar in Korea
JANFiled Additional patents for the human hyaluronidase
2019
NOVEntered License Agreement with top 10 global pharmaceutical company for ALT-B4 technology
OCTEntered Manufacturing Agreement with DM Bio for manufacturing Eylea biosimilar for global phase 3 clinical trial
JULFiled PCT application for proprietary technology of human hyaluronidase for subcutaneous injection
JULSigned a joint development and technology transfer contract with Cristalia for long-acting human growth hormone
JULRegistered patent for antibody-drug conjugates containing modified antibodies (Korea)
JULRegistered process patent for the fermentation of Eylea biosimilar fusion protein (Australia)
JULIND approval for Herceptin biosimilar in China
JUNFiled patent for Herceptin SC for subcutaneous injection (Korea)
JUNRegistered process patent for the fermentation of Eylea biosimilar fusion protein (Japan)
MAYFirst phase 1 IND approval for Eylea Biosimilar in Korea
MAYSigned Option Agreement with global pharmaceutical company for ALT-B4 technology for subcutaneous use of antibody
APRPresented Antibody-drug conjugation (ADC) for breast cancer treatment at the 2019 PEGS Boston Conference
MARFiled patent for Herceptin and other anti-cancer drugs for subcutaneous injection (Korea)
JANSelected as an innovative pharmaceutical company by the Ministry of Health and Welfare

2018
DECCBO expert was recruited for accelerating gloabl license out
DECMutual develpment agreement with DGMIF for the production of antibody-drug conjugate for breast cancer treatment
NOVPresented the development result of antibody-drug conjugate for the treatment of breast cancer in 2018 World ADC conference
SEPAwarded the grand prize of Korean Biotherapeutics Award
AUGCMC specialist was recruited to accelerate the clinical development programs
AUGALT-P7 was designated as an orphan drug for the treatment of gastric cancer from US FDA
JULDeveloped proprietary Hybrozyme technology for subcutaneous injection (the development in the world)
JULCompleted phase 2a clinical trial for long-acting human growth hormone (in Korea)
JULMutual development agreement with Lyncogen Inc, (USA) for the treament of nonalcoholic steatohepatitis, a blue ocean market of 2 billion dollar
JUNCeres F&D Inc., a subsidiary company of Alteogen, was established
JUNMinister of Malaysian Investment Development Authority visitied Alteogen
MAYGrant awarded from Ministry of Trade, Industry and Energy for global commercialization of innovative IP product, long-acting growth hormone.
MAYCompleted preclinical study of Eylea biosimilar in US
MAYDeveloping antibody-drug conjugate (ADC), based on proprietary NexMabTM technology, for the treatment of ovarian cancer
APRSelected for ‘Core technology development project for
Bioindustry’ on NexP™-based long-acting human growth hormone (ALT-P1) development project by Ministry of Trade, Industry and Energy of Korea
MARSigned MOU for establishing JV (with state-owned InnoBio Ventures of Malaysia)
JANReceived Excellence Award in bioprocessing (Asia-Pacific Bioprocessing Excellence Awards 2018)
2017
DECSelected as 2018 Youth-friendly strong small business (Ministry of Employment and Labor of Korea, BEST Wage / BEST Work-life balance / BEST employment stability)
DECSelected as 2017 Excellent Bio-field Company by Ministry of Industry of Korea (Received Minister’s Award by Ministry of Trade, Industry and Energy)
OCTCommenced Clinical Phase II for long-acting human growth hormone (ALT-P1) based on original NexP™ platform technology
OCTBreast cancer antibody-drug conjugate (ADC) selected as Pan-Ministry New Drug Development Project Group for National New Drug Development Project
SEPSigned business agreement for joint ADC development (with Levena Biopharma of China)
AUGCertified as a venture company (Fifth, Venture Investment Company, No. 20170300402)
AUGADC biobetter (ALT-P7) for breast cancer treatment commenced Korea’s first Clinical Phase I
JUNReceived Grand Award at Maekyung Star Audition
MARSigned licensing-out contract for Herceptin biosimilar (with Qilu of China)
JANSelected as a “firm with superior intellectual capacity expertise” (Ministry of Trade, Industry and Energy of Korea)
2016
DECCompleted Clinical Phase I of Herceptin biosimilar (ALT-L2) (Canada)
NOVCEO Soon Jae Park, PhD receives Intellectual Property Entrepreneur Award (Korea Invention Promotion Association Chairman’s Award)
SEPSelected as merit company for regional industry promotion (Awarded by Ministry of Trade, Industry and Energy of Korea)
JULSelected as 2016 National R&D Top 100 Excellence Performance (Ministry of Science of Korea, ICT and Future Planning)
JUNCEO Soon Jae Park, PhD selected as Man of Merit for development of biomedicine industry (Awarded by Minister of Food and Drug Safety of Korea)
JUNSelected for ‘Technology development project for firms with superior intellectual capacity expertise’ on NexP™-based hemophilia medicine development project by Ministry of Trade, Industry and Energy of Korea
APRSelected as 2016 Youth-friendly strong small business (Ministry of Employment and Labor of Korea)
2015
DECSelected as 2015 Superior Company in Bio field by Ministry of Industry of Korea (Awarded by Director of Korea Evaluation Institute of Industrial Technology)
OCTSigned licensing-out contract for ADC breast cancer medicine (ALT-P7) (with 3SBio of China)
SEPCompleted Clinical Phase I testing for long-acting human growth hormone (ALT-P1)
AUGCertified as a venture company (Fourth, Venture Investment Company, No. 20150300299)
2014
DECSelected as a “Firm with superior intellectual capacity expertise” (Ministry of Trade, Industry and Energy of Korea)
DECListed on KOSDAQ
FEBSelected as “IP Star Company” (Korean Intellectual Property Office)
2013
AUGCertified as a venture company (Third, Venture Investment Company, No. 20130300194)
MAYProject for development of antibody biosimilar for curing arthritis selected as Project for Nurturing Strong Global Small Business by Small and Medium Business Administration of Korea
2012
NOVSelected as company with merit for development of urban affairs (Awarded by Mayor of Daejeon, Korea)
APRSelected as a military service waived company (Research center affiliated with venture company) (Military Manpower Administration of Korea)
MARAltos Bioscience, a subsidiary, signed licensing-out contract for animal medicine (with UQ of Brazil)
2011
NOVSigned licensing-out contract for an antibody biosimilar asset (with Cristalia of Brazil)
AUGCertified as a venture company (Second, Venture Investment Company, No. 20110300189)
JUNSigned licensing-out contract for two antibody biosimilar assets (with Cristalia of Brazil)
JUNProject for developing biobetter on breast cancer antibody-drug conjugate medicine selected as Industry Convergence Original Technology Development Project by Ministry of Knowledge Economy of Korea
JUNSelected as Regional Star Company (Ministry of Knowledge Economy of Korea)
2010
DECCEO Soon Jae Park, PhD receives “Top 100 Technologies and the People in Republic of Korea (National Academy Engineering of Korea)
SEPSigned licensing-out contract for long-acting human growth hormone (with CJ CheilJedang of Korea)
JUNCEO Soon Jae Park, PhD inaugurated
2009
AUGCertified as a venture company (First, Technology Assessment Assurance Company, No. 20090107651)
JULResearch center confirmed for the company affiliation (Korea Industrial Technology Association, No. 20092108282)
2008
DECR&D department confirmed for the company affiliation (Korea Industrial Technology Association, No. 2008250266)
MAYCompany establishment